Price History

Hover for the daily close. The dotted line marks the period open.

Compare INGN with… →

INGN Key Statistics

As of Sep 4, 2026

Trading

Open: $5.40
Previous Close: $5.45
Day's Range: 5.37–5.47
52-Week Range: 5.29–9.13
Volume: 216.60K
Beta: 1.58

Valuation

Market Cap: $143.84M
P/E Ratio: unprofitable
P/S ratio: 0.41
EPS (ttm): −0.91

Financials (FY)

Revenue (FY): $348.67M+3.86%
Net Income (FY): −$22.75M
Profit margin: −6.94%
Shares Outstanding: 26.54M
1-Year Return: −33.25%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 247.17K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

INGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+77.28%−72.15%−19.35%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−19.35%
2025	−26.72%
2024	+67.03%
2023	−72.15%
2022	−42.03%
2021	−23.90%
2020	−34.61%
2019	−44.97%
2018	+4.27%
2017	+77.28%
2016 (partial year)	+22.62%

As of September 4, 2026.

INGN Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$348.67M	−$22.75M	−6.5%
2024	$335.71M	−$35.89M	−10.7%
2023	$315.66M	−$102.45M	−32.5%
2022	$377.24M	−$83.77M	−22.2%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$348.67M	$154.27M	−$30.21M	−$22.75M	−6.5%
2024	$335.71M	$154.74M	−$42.52M	−$35.89M	−10.7%
2023	$315.66M	$126.70M	−$76.49M	−$102.45M	−32.5%
2022	$377.24M	$153.53M	−$33.08M	−$83.77M	−22.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

INGN Valuation vs Medical Devices Median

Median of 151 stocks

Metric	INGN	Medical Devices median	vs median
P/S ratio	0.41	2.98	0.1x the median
Profit margin	−6.94%	−1.69%	5.3 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Inogen, Inc. (INGN) is capitalised at $143.84M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 753.

Over the past 52 weeks the price has ranged from $5.29 to $9.13. INGN last closed at $5.42 on September 4, 2026. That is −$0.03 (−0.55%) against the previous close. The latest close sits 2.4% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $348.67M. That is +3.86% against the prior fiscal year, when revenue was $335.71M. The same year closed with a net loss of $22.75M. Profit margin runs at −6.94%. That is 5.3 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −0.91.

Across the 4 fiscal years on file, revenue moves from $377.24M in 2022 to $348.67M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.41 times revenue. On price-to-sales that is 0.1 times the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The reported beta is 1.58. Daily returns over the trailing 10 years annualize to a volatility of 57%. The trailing one-year price return is −33.25%. Measured over 10 years, that is −21.12% a year compounded.

Growth & Income

The record shows no dividend for INGN.

The strongest complete calendar year on file is 2017 at +77.28%; the weakest is 2023 at −72.15%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −19.35% year to date.

Peer Comparison

Inogen, Inc. (INGN) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Inogen, Inc.	INGN	$143.84M	—
Abbott Laboratories	ABT	$187.45B	35.1
Medtronic plc.	MDT	$120.46B	22.9
Stryker Corporation	SYK	$116.27B	31.9

The Medical Devices industry average P/E ratio is 26.8x. Inogen, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

MDT

Medtronic plc.

$120.46B

SYK

Stryker Corporation

$116.27B

BSX

Boston Scientific Corporation

$69.27B

EW

Edwards Lifesciences Corporation

$51.82B

DXCM

DexCom, Inc.

$33.17B

View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Inogen, Inc.

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.

Visit website →

Inogen, Inc. (INGN) Stock Analysis